Metelimumab (CAT-192) is a human IgG4 monoclonal antibody that neutralizes TGF beta 1 which had been chosen for further development for the treatment of diffuse cutaneous systemic sclerosis, also known as scleroderma.
This downregulation sees the removal of post-transcriptional repression of TGF-β1 and TGF-β receptor type II (TGF-βRII), and consequent collagen production.
Multiple miR-744 binding sites have been identified in the proximal 3' untranslated region of transforming growth factor beta 1 (TGF-β1).
Beta | Tau Beta Pi | Phi Beta Sigma | beta | Zeta Beta Tau | TGF beta 1 | Beta Gamma Sigma | The Beta Band | Tau Beta Sigma | Phi Beta Kappa Society | Beta Israel | TGF beta receptor 2 | TGF alpha | National Beta Club | Beta (plant) | Beta (letter) | Beta-Hexachlorocyclohexane | Beta Flight | Beta Alpha Psi | VHS or Beta | Steroid 11-beta-hydroxylase | Gamma Phi Beta | Epoetin beta | Beta (typeface) | Beta Sigma Phi | Beta-galactosidase | beta decay | Beta Crucis | Beta Centauri | Beta amyloid |
EMT can be induced by a number of genes including Snail, Twist, Goosecoid, and TGF-beta 1.